Among drug classes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a statistically significant reduction in dementia, but not sodium-glucose cotransporter-2 inhibitors (SGLT2is). Here, SLC5A2 is linked to dementia.